The stock of Biodexa Pharmaceuticals Plc ADR (BDRX) has seen a -33.77% decrease in the past week, with a -2.91% drop in the past month, and a -34.64% decrease in the past quarter. The volatility ratio for the week is 12.19%, and the volatility levels for the past 30 days are at 13.55% for BDRX. The simple moving average for the past 20 days is 0.18% for BDRX’s stock, with a -67.77% simple moving average for the past 200 days.
Is It Worth Investing in Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) Right Now?
The 36-month beta value for BDRX is also noteworthy at 1.52. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of BDRX on May 08, 2024 was 3.36M shares.
BDRX) stock’s latest price update
The stock of Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) has decreased by -9.91 when compared to last closing price of 1.11.Despite this, the company has seen a loss of -33.77% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-30 that April 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that’s its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024. Carol Burke, MD, the Principal Investigator, will present the six month data (NCT04230499) in an oral presentation at the meeting.
Analysts’ Opinion of BDRX
Many brokerage firms have already submitted their reports for BDRX stocks, with Ladenburg Thalmann repeating the rating for BDRX by listing it as a “Buy.” The predicted price for BDRX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on February 08, 2024 of the current year 2024.
BDRX Trading at -10.85% from the 50-Day Moving Average
After a stumble in the market that brought BDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.19% of loss for the given period.
Volatility was left at 13.55%, however, over the last 30 days, the volatility rate increased by 12.19%, as shares surge +1.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.06% lower at present.
During the last 5 trading sessions, BDRX fell by -33.77%, which changed the moving average for the period of 200-days by -82.14% in comparison to the 20-day moving average, which settled at $0.9987. In addition, Biodexa Pharmaceuticals Plc ADR saw -62.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BDRX
Current profitability levels for the company are sitting at:
- -17.33 for the present operating margin
- -10.82 for the gross margin
The net margin for Biodexa Pharmaceuticals Plc ADR stands at -18.58. The total capital return value is set at -1.33. Equity return is now at value -180.18, with -87.62 for asset returns.
Based on Biodexa Pharmaceuticals Plc ADR (BDRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -14.71.
Currently, EBITDA for the company is -7.65 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of -13.96. The receivables turnover for the company is 0.54for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In summary, Biodexa Pharmaceuticals Plc ADR (BDRX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
